New antiviral compounds.
Several potent and selective antiviral agents against herpes virus infections have been developed. However, the majority of compounds against other viral diseases has not yet reached such high standard. Based on progress in molecular virology it can, however, be anticipated that similar concepts of selective inhibition will also be developed for other virus groups. In addition to virus-induced enzymes, viral proteins other than enzymes with specific activities will be identified. The identification of active sites will lead to the design of new and specific inhibitors. Moreover, studies on the mode of action of the huge number of known antiviral compounds may provide the basis for new and potent approaches to specific virus chemotherapy. New inhibitors of viral replication may also be derived from 2'-5'A and other mediators of the interferon induced antiviral state. However, since 2'-5'A does not enter cells, is rapidly degraded by phosphodiesterases, and affects viral and cellular protein synthesis, only analogs which do not have these disadvantages may qualify as antiviral drugs. In addition to refinements at the molecular level quantitative assays for a better evaluation of antiviral agents for clinical use are required. For clinical trials, rapid diagnosis, early initiation of treatment, and quantitative evaluation of the antiviral effects of a drug need to be developed. Moreover, new methods of drug delivery and/or drug targeting will improve potency and selectivity of antiviral compounds. Drug carriers have already successfully been used in cancer therapy (Poste and Fidler, 1981) they should be also applicable to virus chemotherapy. Finally, a better understanding of the pathogenesis and the natural course of viral diseases will contribute to the development of more effective and safe antiviral agents.
G
G
Streissle
A
A
Paessens
H
H
Oediger
D000227:Adenine Nucleotides / Q000494:pharmacology; D000818:Animals; D000914:Antibodies, Viral / Q000008:administration & dosage; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001370:Axonal Transport / Q000187:drug effects; D002352:Carrier Proteins / Q000008:administration & dosage; D006801:Humans; D007369:Interferon Inducers / Q000494:pharmacology; D008081:Liposomes; D009843:Oligoribonucleotides / Q000494:pharmacology; D014777:Virus Diseases / Q000188:drug therapy; D018406:Virus Physiological Phenomena; D014779:Virus Replication / Q000187:drug effects; D014780:Viruses / Q000187:drug effects / Q000254:growth & development
D000227:Adenine Nucleotides; D000914:Antibodies, Viral; D000998:Antiviral Agents; D002352:Carrier Proteins; D007369:Interferon Inducers; D008081:Liposomes; D009843:Oligoribonucleotides; C023505:2',5'-oligoadenylate